Regencell Bioscience Holdings Ltd RGC
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.72
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $948.3K | $1.1M | $1.6M | $2.5M | $438.3K | $386.2K | $228.2K | — |
| SG&A | $2.8M | $3.5M | $4.4M | $5.1M | $941.5K | $311.9K | $159.1K | — |
| Total operating expenses | $3.8M | $4.7M | $6.3M | $7.6M | $1.4M | $812.4K | $391.0K | — |
| Operating income | -$3.8M | -$4.7M | -$6.3M | -$7.6M | -$1.4M | -$812.4K | -$391.0K | — |
| Pre-tax income | -$3.6M | -$4.4M | -$6.1M | -$7.6M | -$1.3M | -$812.4K | -$391.0K | — |
| Net income | -$3.6M | -$4.3M | -$5.9M | -$7.4M | -$1.3M | -$812.4K | -$391.0K | — |
| EPS, basic | -0.72 | -0.87 | -1.19 | -0.58 | 0.13 | 0.08 | — | — |
| EPS, diluted | -0.72 | -0.87 | -1.19 | -0.58 | -0.13 | -0.08 | — | — |
| Shares, diluted (wtd. avg.) | 494.5M | 494.5M | 494.5M | 12.8M | 10.0M | 10.0M | 0 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.4M | $3.0M | $1.6M | $6.4M | $59.4K | $387.0K | $243.3K | $153.3K |
| Short-term investments | $2.5M | $5.0M | $10.0M | $10.0M | — | — | — | — |
| Total current assets | $4.9M | $8.1M | $11.6M | $16.4M | $66.8K | $387.0K | — | — |
| Property, plant and equipment | $215.4K | $141.7K | $440.8K | $712.6K | $81.9K | $108.3K | — | — |
| Total assets | $5.8M | $8.4M | $12.6M | $18.0M | $340.1K | $514.0K | — | — |
| Short-term debt | — | — | — | — | — | $3.0M | — | — |
| Total current liabilities | $663.7K | $193.6K | $606.9K | $577.8K | $4.3M | $3.2M | — | — |
| Total liabilities | $895.3K | $219.5K | $632.3K | $938.0K | $4.3M | $3.2M | — | — |
| Retained earnings | -$25.2M | -$21.6M | -$17.3M | -$11.4M | -$4.0M | -$2.7M | — | — |
| Total equity | $4.9M | $8.2M | $12.0M | $17.1M | -$4.0M | -$2.7M | -$1.8M | -$1.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.1M | -$4.0M | -$5.0M | -$5.3M | -$767.3K | -$726.6K | -$391.0K | — |
| Depreciation and amortisation | $77.7K | $305.8K | $293.1K | $150.1K | $26.5K | $9.5K | — | — |
| Stock-based compensation | $244.8K | $449.3K | $922.6K | $2.8M | — | — | — | — |
| Capital expenditure | $152.7K | $5.4K | $27.4K | $780.9K | — | $117.8K | — | — |
| Investing cash flow | $2.7M | $5.2M | $59.0K | -$10.8M | — | -$117.8K | — | — |
| Financing cash flow | — | $102.3K | $134.9K | $22.4M | $439.7K | $988.1K | $481.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-25-104686.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Operating cash flow
- Total current assets
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$391.0K | -$726.6K | -$767.3K | -$5.3M | -$5.0M | -$4.0M | -$3.1M |
| Total current assets | — | — | $387.0K | $66.8K | $16.4M | $11.6M | $8.1M | $4.9M |
Others in SIC 2833
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DFTX | Definium Therapeutics, Inc. | $5.12B | — | — |
| TRLV | Trulieve Cannabis Corp. | $2.33B | — | -0.4% |
| CRON | Cronos Group Inc. | $1.20B | — | 24.6% |
| TLRY | Tilray Brands, Inc. | $612.9M | — | 11.5% |
| CGC | Canopy Growth Corp | $411.5M | — | — |
| USNA | USANA HEALTH SCIENCES INC | $276.4M | 25.8x | 8.3% |
| NAGE | Niagen Bioscience, Inc. | $250.8M | 15.8x | 29.9% |
| FTLF | FITLIFE BRANDS, INC. | $92.2M | 15.6x | 26.4% |